Kamada Signs Deal To Supply Israel’s Health Ministry With COVID-19 Antibody Drug
Kamada developed a plasma-derived, investigational antibody treatment for COVID-19 currently under trial; interim results show promise.
October 19, 2020
Early Results For COVID-19 Trial With Antibody Drug Show 90% Improvement Rate
The trial involves 12 hospitalized but non-ventilated COVID-19 patients with pneumonia; 11 of them have been discharged, Kamada says.
September 09, 2020
Small Trial For COVID-19 Antibody Drug Gets Flying Start In Jerusalem
Hadassah hospital gave 3 people a new drug made from antibodies from people who had had coronavirus; they are all now home after an ‘astonishing’ recovery.
August 16, 2020
Israeli Biopharma Company Kamada To Roll Out Antibody Treatment For COVID-19
The Rehovot-based firm said it completed the manufacturing of the first batch of its plasma-derived IgG product for the novel coronavirus.
June 21, 2020
‘Kamada’ Obtains FDA Approval For Cystic Fibrosis Drug Trial
Israeli bio-pharmaceutical company Kamada announced that it has obtained FDA approval to conduct a clinical trial in the US for the company’s next generation drug for the treatment of cystic fibrosis. The drug is an inhalable version of company’s AAT drug (Alpha-1 Antitrypsin deficiency). The current FDA approval is partly based on successful pre-clinical trials of the […]
March 11, 2012